Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

PURPOSE The 21-gene recurrence score (RS) assay quantifies the likelihood of distant recurrence in women with estrogen receptor-positive, lymph node-negative breast cancer treated with adjuvant tamoxifen. The relationship between the RS and chemotherapy benefit is not known. METHODS The RS was measured in tumors from the tamoxifen-treated and tamoxifen plus chemotherapy-treated patients in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B20 trial. Cox proportional hazards models were utilized to test for interaction between chemotherapy treatment and the RS. RESULTS A total of 651 patients were assessable (227 randomly assigned to tamoxifen and 424 randomly assigned to tamoxifen plus chemotherapy). The test for interaction between chemotherapy treatment and RS was statistically significant (P = .038). Patients with high-RS (> or = 31) tumors (ie, high risk of recurrence) had a large benefit from chemotherapy (relative risk, 0.26; 95% CI, 0.13 to 0.53; absolute decrease in 10-year distant recurrence rate: mean, 27.6%; SE, 8.0%). Patients with low-RS (< 18) tumors derived minimal, if any, benefit from chemotherapy treatment (relative risk, 1.31; 95% CI, 0.46 to 3.78; absolute decrease in distant recurrence rate at 10 years: mean, -1.1%; SE, 2.2%). Patients with intermediate-RS tumors did not appear to have a large benefit, but the uncertainty in the estimate can not exclude a clinically important benefit. CONCLUSION The RS assay not only quantifies the likelihood of breast cancer recurrence in women with node-negative, estrogen receptor-positive breast cancer, but also predicts the magnitude of chemotherapy benefit.

[1]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.

[2]  R. Simon,et al.  The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. , 1978, The New England journal of medicine.

[3]  R. W. Baldwin,et al.  Tumour aneuploidy, prognostic parameters and survival in primary breast cancer. , 1987, British Journal of Cancer.

[4]  R. Camplejohn,et al.  Histological grade, elastosis, DNA ploidy and the response to chemotherapy of breast cancer. , 1987, British Journal of Cancer.

[5]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[6]  Robert Gray,et al.  Flexible Methods for Analyzing Survival Data Using Splines, with Applications to Breast Cancer Prognosis , 1992 .

[7]  T. Aas,et al.  Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. , 1996, Acta oncologica.

[8]  B Fisher,et al.  Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. , 1997, Journal of the National Cancer Institute.

[9]  K. Franssila,et al.  A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer. , 1998, British Journal of Cancer.

[10]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[11]  S. Martino,et al.  Prediction of Node-Negative Breast Cancer Outcome by Histologic Grading and S-Phase Analysis by Flow Cytometry: An Eastern Cooperative Oncology Group Study (2192) , 2001, American journal of clinical oncology.

[12]  S. Edge,et al.  NCCN: Breast cancer. , 2001, Cancer control : journal of the Moffitt Cancer Center.

[13]  Robert J. Mayer,et al.  National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.

[14]  R. Bast,et al.  2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Stec,et al.  Global Gene Expression Changes During Neoadjuvant Chemotherapy for Human Breast Cancer , 2002, Cancer journal.

[16]  E. Feuer,et al.  Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. , 2002, Journal of the National Cancer Institute.

[17]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[18]  Norman Wolmark,et al.  Multi-gene Rt-pcr assay for predicting recurrence in node negative breast cancer patients-nsabp studies B-20 and B-14 , 2003 .

[19]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  C. Cordon-Cardo,et al.  A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.

[21]  R. Salunga,et al.  Gene expression profiles of human breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Syed Mohsin,et al.  Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.

[23]  R. Gelber,et al.  Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[25]  A. Luini,et al.  Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors , 2004, Clinical Cancer Research.

[26]  J. Stec,et al.  Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Debjani Dutta,et al.  Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. , 2004, The American journal of pathology.

[28]  J. Bryant,et al.  Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials , 2004, The Lancet.

[29]  I. Henderson,et al.  The relationship between prognostic and predictive factors in the management of breast cancer , 2004, Breast Cancer Research and Treatment.

[30]  Daniel F. Hayes,et al.  Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful? , 2004, Breast Cancer Research and Treatment.

[31]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[32]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[33]  Program for the Assessment of Clinical Cancer Tests (PACCT): implementing promising assays into clinical practice , 2005, Expert review of molecular diagnostics.

[34]  Roman Rouzier,et al.  Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.